We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ACS Global Inc (CE) | USOTC:AMCY | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.00 | 0.00 | 01:00:00 |
Mr. Anthony Dudzinski, the CEO of AMCY, stated, "Because RAPP is a publicly traded reporting company, we believe that the sale of AMCY's assets to RAPP for 21,000,000 shares of RAPP common stock will enhance our shareholders' value."
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors including, but not limited to, the stem cell industry, RAPP's stock price and trading volume, general economic conditions, RAPP's business success and or failure, and its continued development of the assets it acquired from AMCY, the financial position of RAPP and RAPP's ability to successfully commercialize the business it acquired from AMCY when it acquired AMCY's assets.
For More Information, contact: Investor Relations American CryoStem Corporation 188 East Bergen Place, Suite 204 Red Bank, NJ 07701 Phone: 732-747-1007 Fax: 732-747-7782 www.americancryostem.com
1 Year ACS Global (CE) Chart |
1 Month ACS Global (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions